BioSpace News Archive

Amicus Therapeutics (Nasdaq: FOLD), today announced the acceptance of two abstracts for presentation at the American Society of Gene & Cell Therapy 24th Annual Meeting being held virtually, May 11-14, 2021. Accepted abstracts will highlight preclinical data from the Company’s Fabry and Pompe gene therapy programs, which Amicus is developing with the Gene Therapy Program of the Perelman School of Medicine at the University of Pennsylvania.

Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Wednesday, May 12 at 5:00 p.m. ET.

First Quarter Total Net Revenue Increased 30% to $34.6 Million Full-Year 2021 Revenue Guidance Raised to $165-$168 Million Conference Call Today at 8:30am Eastern Time

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the first quarter ended March 31, 2021, prior to the open of the U.S. financial markets on Wednesday, May 12, 2021.

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading provider of surgical services, today announced results for the first quarter ended March 31, 2021.

Initial data anticipated in the third quarter of 2021 Top-line data from the ongoing Phase 1b proof of concept clinical trial in relapsed or refractory multiple myeloma patients anticipated in the second half of 2021

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results and provide a business update on Wednesday, May 12, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

ANJESO ® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q4’20 Average Sales per Account Increased 30% in Q1 compared to Q4’20 Richard S. Casten Strengthens Management Team in Chief Financial Officer Role Management to Host Investor Conference Call and Webcast Today at 8:00 a.m. ET

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021 , after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results

Focused on robust expansion throughout Canada, the U.S. and Europe by way of strategic acquisitions and organic growth of services to existing patients.